Mapi - Pharma (Mapi - Pharma) EBITDA Margin % : 0.00% (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mapi - Pharma's EBITDA for the six months ended in Jun. 2015 was $-1.91 Mil. Mapi - Pharma's Revenue for the six months ended in Jun. 2015 was $0.00 Mil. Therefore, Mapi - Pharma's EBITDA margin for the quarter that ended in Jun. 2015 was 0.00%.

Mapi - Pharma EBITDA Margin % Historical Data

The historical data trend for Mapi - Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma EBITDA Margin % Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

EBITDA Margin %

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
EBITDA Margin %	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's EBITDA Margin % falls into.

Mapi - Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Mapi - Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2014 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2014 )	/	Revenue (A: Dec. 2014 )
	=	-6.745	/	0
	=	%

Mapi - Pharma's EBITDA Margin % for the quarter that ended in Jun. 2015 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2015 )	/	Revenue (Q: Jun. 2015 )
	=	-1.91	/	0
	=	%

Mapi - Pharma (NAS:MAPI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Mapi - Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.